Abdominal Pain and Yellowing of Skin: Could It Be Cholangiocarcinoma?

When the skin turns yellow and the abdomen aches without an obvious cause, it is easy to assume something temporary, such as an infection, a dietary issue, or a passing stomach upset. In some cases, however, these are the first visible signs of cholangiocarcinoma, a cancer of the bile ducts that is characteristically silent until it has already progressed.

Cholangiocarcinomas are highly heterogeneous tumours that commonly share a poor prognosis. These tumours usually develop and progress silently; by the time they are detected, it is often too late for curative surgical intervention. Due to their asymptomatic nature, they are usually diagnosed when the disease is advanced.

Understanding what cholangiocarcinoma is, who is at risk, and which symptoms merit prompt evaluation can make a meaningful difference in treatment outcome. At RGCIRC, bile duct cancer is managed by the Department of GI Oncosurgery and Liver Transplant, working within a multidisciplinary framework that brings together surgical oncologists, medical oncologists, radiation oncologists, gastroenterologists, radiologists, and pathologists.

What is Cholangiocarcinoma?

The bile ducts are a network of thin tubes that carry bile, a digestive fluid produced by the liver, to the small intestine, where it helps break down fats. Cholangiocarcinoma develops when the cells lining these ducts undergo genetic changes that cause them to grow uncontrollably, forming a tumour that can block bile flow and spread to nearby structures.

Cholangiocarcinoma accounts for a small proportion of gastrointestinal cancers, around 3%, and is most often diagnosed in older adults. It is more common in men and is seen more frequently in Asian populations, partly due to risk factors such as hepatitis B infection and certain parasitic infections affecting the liver and bile ducts.

One of the key challenges with this cancer is delayed detection. Because the bile ducts are deep within the body, early tumours often do not cause noticeable symptoms. As a result, many cases are diagnosed only after signs such as jaundice or abdominal discomfort appear, by which time the disease may already be advanced.

Types of Bile Duct Cancer

Cholangiocarcinoma is classified based on where it develops within the bile duct system. This distinction is clinically important, as each type differs in presentation, risk profile, and treatment approach. The main types include:

Intrahepatic Cholangiocarcinoma

Intrahepatic cholangiocarcinoma (iCCA) arises from the small bile ducts within the liver. It accounts for about 10 to 20% of cases. Because it develops deep within the liver, early symptoms are often absent. Patients may experience vague abdominal discomfort, fatigue, or unexplained weight loss. In India, a significant proportion of cases are diagnosed at an advanced stage due to these subtle early signs.

Perihilar Cholangiocarcinoma (Klatskin Tumour)

This type develops at the junction where the right and left bile ducts meet just outside the liver. It is the most common form of cholangiocarcinoma. Due to its location, it often causes bile duct obstruction early, leading to symptoms such as jaundice. Surgical treatment in this region is complex because of its proximity to major blood vessels.

Distal Cholangiocarcinoma

Distal cholangiocarcinoma occurs in the lower part of the bile duct near the pancreas and small intestine. It is generally more amenable to surgical treatment, often through a procedure called pancreaticoduodenectomy (Whipple procedure). Jaundice is usually an early and prominent symptom in this subtype due to blockage of bile flow.

Understanding these types helps guide diagnosis and treatment planning, particularly in determining surgical feasibility and expected outcomes.

Signs and Symptoms

Cholangiocarcinoma often presents late, as early symptoms are either mild or absent. Many patients first notice painless jaundice, vague upper abdominal discomfort, or unexplained weight loss. In some cases, particularly intrahepatic disease, jaundice may appear only in advanced stages.

When to Seek Specialist Evaluation

Jaundice without a clear cause, especially when accompanied by dark urine, pale stools, itching, or abdominal discomfort, should be evaluated without delay.

At RGCIRC, patients with these symptoms undergo a rapid and coordinated diagnostic workup led by specialised GI Oncosurgery and Interventional Gastroenterology teams, ensuring timely diagnosis and appropriate care.

Causes and Risk Factors of Cholangiocarcinoma

While several risk factors are known, many cases of cholangiocarcinoma occur without a clearly identifiable cause. The disease is often linked to chronic inflammation and injury of the bile ducts, which over time can lead to malignant changes. Factors that increase the risk of this type of cancer include:

• Primary Sclerosing Cholangitis (PSC)
• Hepatitis B and C Infection
• Liver Cirrhosis
• Bile Duct Stones and Chronic Inflammation
• Liver Fluke Infection
• Obesity and Type 2 Diabetes
• Prior Biliary Conditions or Surgery

Congenital abnormalities such as choledochal cysts and previous bile duct surgeries can increase long-term risk due to persistent inflammation.

Age and Sex

Cholangiocarcinoma is more commonly diagnosed in men and typically occurs after the age of 60. Increasing age is an independent risk factor across all types.

Awareness of these risk factors is important, particularly for individuals with underlying liver or biliary conditions, as it allows for closer monitoring and earlier detection.

How is Cholangiocarcinoma Diagnosed?

At RGCIRC, investigations are carefully sequenced to build a complete clinical picture.

Liver Function Tests

Blood tests measuring bilirubin, alkaline phosphatase, gamma-GT, ALT, and AST provide the first indication of bile duct obstruction or liver involvement. Elevated bilirubin and alkaline phosphatase in a patient with jaundice typically prompt further evaluation.

Tumour Marker Tests

Markers such as CA 19-9 and CEA are often elevated in cholangiocarcinoma. While not specific, raised levels in the setting of biliary obstruction increase suspicion and guide the need for detailed imaging.

Imaging Tests

Imaging plays a central role in detecting the tumour and assessing its extent. Common modalities include:

• Ultrasound: First-line test to identify bile duct dilatation or liver lesions
• Contrast-enhanced CT: Evaluates tumour size, spread, and staging
• MRI with MRCP: Provides detailed imaging of the bile ducts and tumour involvement
• PET-CT: Used to detect distant spread in selected cases

Endoscopic Tests

• ERCP (Endoscopic Retrograde Cholangiopancreatography): Allows direct imaging of the bile ducts and enables interventions such as stent placement. Tissue samples can also be collected
• Endoscopic Ultrasound (EUS): Helps assess nearby lymph nodes and allows guided biopsy of suspicious areas

Percutaneous Transhepatic Cholangiography (PTC)

PTC is used when ERCP is not feasible. A needle is inserted through the skin into the liver to access the bile ducts. It helps relieve obstruction and allows sample collection when required.

Biopsy and Molecular Testing

A biopsy confirms the diagnosis and identifies the cancer subtype. Advanced molecular testing, including next-generation sequencing, may be performed to detect specific mutations such as FGFR2, IDH1/2, or HER2, which can guide targeted therapy decisions.

This comprehensive diagnostic pathway ensures accurate staging and helps determine the most effective treatment strategy for each patient.

How is Cholangiocarcinoma Treated?

Every case is reviewed by a multidisciplinary tumour board to ensure a personalised, evidence-based treatment plan.

Surgery

Surgery remains the only potentially curative option and is considered when the tumour can be completely removed. The approach varies by tumour location:

• Intrahepatic CCA: Liver resection (removal of the affected segment or lobe)
• Perihilar CCA: Complex resection involving the bile duct junction, often combined with liver resection and lymph node removal
• Distal CCA: Whipple procedure (pancreaticoduodenectomy), removing the distal bile duct along with part of the pancreas

Achieving clear surgical margins is critical for long-term outcomes.

Chemotherapy

Chemotherapy is used in both curative and palliative settings:

• First-line regimen: Gemcitabine with cisplatin for advanced disease
• Adjuvant therapy: Given after surgery in selected cases to reduce recurrence risk
• Advanced disease: Helps control tumour growth and improve symptoms

Targeted Therapy

Molecular testing has enabled more personalised treatment. Targeted therapies may be used in patients with specific mutations, such as:

• FGFR2 fusions
• IDH1/2 mutations
• HER2 amplification

These therapies are typically used in advanced or second-line settings based on tumour profiling.

Immunotherapy

Immunotherapy has become an important option in selected patients. Drugs such as durvalumab and pembrolizumab, often combined with chemotherapy, have shown improved outcomes in advanced biliary cancers, particularly in patients with specific molecular features.

Biliary Drainage

For patients with obstructive jaundice, relieving bile duct blockage is essential. This is achieved through:

• Endoscopic stenting (ERCP)
• Percutaneous transhepatic drainage

These procedures help improve liver function, relieve symptoms, and allow further treatment to proceed safely.

A combination of these approaches is often required, with the goal of controlling the disease, improving quality of life, and, where possible, achieving long-term remission.

Why Choose RGCIRC for Bile Duct Cancer Care

Cholangiocarcinoma requires highly specialised care, and outcomes are closely linked to the expertise and experience of the treating centre. At RGCIRC, patients benefit from a comprehensive, multidisciplinary approach backed by advanced infrastructure and clinical excellence.

Dedicated GI Oncosurgery and Liver Transplant Expertise

RGCIRC’s Department of GI Oncosurgery and Liver Transplant has extensive experience in the surgical management of cholangiocarcinoma across all subtypes, including complex hepatic resections for intrahepatic disease, hilar resections for perihilar tumours, and Whipple procedures for distal disease. The department also offers liver transplantation evaluation for selected patients with very early intrahepatic CCA meeting established criteria.

Multidisciplinary Tumour Board Review

Every cancer case is reviewed by a team of specialists, including surgical oncologists, medical oncologists, radiation oncologists, interventional gastroenterologists, radiologists, and pathologists. This ensures accurate assessment of resectability and a well-planned treatment sequence based on the latest evidence.

Molecular Profiling and Precision Oncology

RGCIRC’s molecular laboratory offers next-generation sequencing for tumour tissue, enabling identification of FGFR2 fusions, IDH1/2 mutations, HER2 amplification, and other actionable alterations that determine eligibility for targeted therapy. This capability is particularly important in cholangiocarcinoma, where molecular subtyping is now a standard component of treatment planning for advanced disease.

Book a Consultation at RGCIRC

If you or someone you know is experiencing unexplained jaundice, persistent right upper abdominal pain, or dark urine alongside pale stools, do not delay seeking specialist evaluation. Early assessment at a dedicated oncology centre is the most important step toward an accurate diagnosis and timely treatment.

To book an appointment with a specialist at RGCIRC, simply Call +91-11-4702 2222 (Rohini) / +91-11-4582 2222 (Niti Bagh, South Delhi) Book online at care.rgcirc.org | Download the RGCI Care app on iOS and Android

OPD Hours: Monday to Saturday, 9:00 AM to 5:00 PM | Emergency Services: 24×7 at both campuses

Frequently Asked Questions (FAQs)

1. How common is bile duct cancer?

Cholangiocarcinoma is rare globally, accounting for approximately 3% of gastrointestinal cancers. In India, it is more commonly encountered than in Western countries due to the higher prevalence of hepatitis B, biliary stone disease, and other associated risk factors. Its incidence has been rising worldwide over the past two decades.

2. How curable is bile duct cancer?

Cholangiocarcinoma is potentially curable only when detected at an early stage and when complete surgical resection with clear margins is achievable. For patients with localised disease who undergo curative resection, five-year survival rates of 20 to 40% are reported depending on subtype and margin status. Advanced and metastatic disease is managed with systemic therapy aimed at disease control rather than cure.

3. How fast does bile duct cancer spread?

Cholangiocarcinoma is generally an aggressive cancer. Perihilar and distal subtypes tend to cause biliary obstruction relatively early, which prompts investigation. Intrahepatic cholangiocarcinoma may grow silently for longer, and many patients present with locally advanced or metastatic disease at first diagnosis. The rate of spread varies by subtype, grade, and individual tumour biology.

4. Can bile duct cancer be inherited?

Most cholangiocarcinomas are sporadic and not inherited. A small proportion occur in the context of hereditary conditions, including primary sclerosing cholangitis with inflammatory bowel disease, Lynch syndrome (mismatch repair deficiency), and choledochal cyst syndromes. Individuals with a family history of biliary or colorectal cancer may benefit from earlier clinical evaluation.

5. Does bile duct cancer recur?

Yes. Recurrence after apparently curative resection is common, occurring in approximately 50 to 70% of patients within two to three years of surgery. Regular surveillance with imaging and CA 19-9 monitoring following resection is a standard clinical practice to detect recurrence early, when further treatment options are most effective.

6. What foods should be avoided with bile duct cancer?

Patients with cholangiocarcinoma or obstructive jaundice benefit from avoiding high-fat foods that increase biliary demand, alcohol in all forms, and processed or preserved foods. A clinical dietician consultation, available at RGCIRC as part of the oncology care pathway, provides personalised nutritional guidance based on the patient’s treatment phase and liver function.

7. Can bile duct cancer cause back pain?

Yes, in some patients. Back pain may develop when the tumour invades or compresses structures in the retroperitoneum or when the cancer has spread to the spine or surrounding tissues. Back pain in a patient with known or suspected biliary disease warrants imaging to exclude vertebral or retroperitoneal involvement.